{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:06:03Z","timestamp":1793048763786,"version":"4.5.0"},"reference-count":14,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A novel oncogenic mutation (FIP1L1-PDGFRA), which results in a constitutively activated platelet-derived growth factor receptor-\u03b1 (PDGFRA), has been invariably associated with a primary eosinophilic disorder. The current study examines both the prevalence and the associated clinicopathologic features of this mutation in a cohort of 89 adult patients presenting with an absolute eosinophil count (AEC) of higher than 1.5 \u00d7 109\/L. A fluorescence in situ hybridization (FISH)\u2013based strategy was used to detect FIP1L1-PDGFRA in bone marrow cells. None of 8 patients with reactive eosinophilia displayed the abnormality, whereas the incidence of FIP1L1-PDGFRA in the remaining 81 patients with primary eosinophilia was 14% (11 patients). None (0%) of 57 patients with the hypereosinophilic syndrome (HES) but 10 (56%) of 19 patients with systemic mast cell disease associated with eosinophilia (SMCD-eos) carried the specific mutation. The bone marrow mast cell infiltration pattern in FIP1L1-PDGFRA+ SMCD-eos was distinctly diffuse with loose tumoral aggregates. Treatment with low-dose imatinib (100 mg\/d) produced complete and durable responses in all 8 FIP1L1-PDGFRA+ cases treated. In contrast, only 40% partial response rate was seen in 10 HES cases. FIP1L1-PDGFRA is a relatively infrequent but treatment-relevant mutation in primary eosinophilia that is indicative of an underlying systemic mastocytosis.<\/jats:p>","DOI":"10.1182\/blood-2004-03-0787","type":"journal-article","created":{"date-parts":[[2004,7,30]],"date-time":"2004-07-30T00:27:15Z","timestamp":1091147235000},"page":"3038-3045","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":253,"title":["FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia"],"prefix":"10.1182","volume":"104","author":[{"given":"Animesh","family":"Pardanani","sequence":"first","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Laboratory Genetics, and Hematopathology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie R.","family":"Brockman","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Laboratory Genetics, and Hematopathology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah F.","family":"Paternoster","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Laboratory Genetics, and Hematopathology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather C.","family":"Flynn","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Laboratory Genetics, and Hematopathology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Laboratory Genetics, and Hematopathology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Laboratory Genetics, and Hematopathology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Liang","family":"Ho","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Laboratory Genetics, and Hematopathology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Yang","family":"Li","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Laboratory Genetics, and Hematopathology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon W.","family":"Dewald","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Laboratory Genetics, and Hematopathology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Laboratory Genetics, and Hematopathology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222382105800_REF1","doi-asserted-by":"crossref","unstructured":"Brito-Babapulle F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol. 2003;121: 203-223.","DOI":"10.1046\/j.1365-2141.2003.04195.x"},{"key":"2020021222382105800_REF2","doi-asserted-by":"crossref","unstructured":"Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002; 359: 1577-1578.","DOI":"10.1016\/S0140-6736(02)08505-7"},{"key":"2020021222382105800_REF3","doi-asserted-by":"crossref","unstructured":"Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348: 1201-1214.","DOI":"10.1056\/NEJMoa025217"},{"key":"2020021222382105800_REF4","doi-asserted-by":"crossref","unstructured":"Pardanani AD, Elliott MA, Reeder TL, et al. Imatinib therapy for systemic mast cell disease. Lancet. 2003;362: 535-536.","DOI":"10.1016\/S0140-6736(03)14115-3"},{"key":"2020021222382105800_REF5","doi-asserted-by":"crossref","unstructured":"Pardanani AD, Reeder TL, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood2003;101: 3391-3397.","DOI":"10.1182\/blood-2002-10-3103"},{"key":"2020021222382105800_REF6","doi-asserted-by":"crossref","unstructured":"Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101: 4714-4716.","DOI":"10.1182\/blood-2003-01-0081"},{"key":"2020021222382105800_REF7","doi-asserted-by":"crossref","unstructured":"Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101: 4660-4666.","DOI":"10.1182\/blood-2003-01-0006"},{"key":"2020021222382105800_REF8","doi-asserted-by":"crossref","unstructured":"Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood. 2003;102: 3093-3096.","DOI":"10.1182\/blood-2003-05-1627"},{"key":"2020021222382105800_REF9","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumors: tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer (IARC) Press; 2001: 291-300."},{"key":"2020021222382105800_REF10","doi-asserted-by":"crossref","unstructured":"Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344: 1031-1037.","DOI":"10.1056\/NEJM200104053441401"},{"key":"2020021222382105800_REF11","doi-asserted-by":"crossref","unstructured":"Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347: 481-487.","DOI":"10.1056\/NEJMoa020150"},{"key":"2020021222382105800_REF12","doi-asserted-by":"crossref","unstructured":"Pardanani A, Reeder TL, Kimlinger TK, et al. Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res. 2003;27: 739-742.","DOI":"10.1016\/S0145-2126(02)00303-X"},{"key":"2020021222382105800_REF13","doi-asserted-by":"crossref","unstructured":"Escribano L, Diaz-Agustin B, Nunez R, Prados A, Rodriguez R, Orfao A. Abnormal expression of CD antigens in mastocytosis. Int Arch Allergy Appl Immunol. 2002;127: 127-132.","DOI":"10.1159\/000048183"},{"key":"2020021222382105800_REF14","doi-asserted-by":"crossref","unstructured":"Miranda RN, Esparza AR, Sambandam S, Medeiros LJ. Systemic mast cell disease presenting with peripheral blood eosinophilia. Hum Pathol. 1994;25: 727-730.","DOI":"10.1016\/0046-8177(94)90308-5"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/10\/3038\/1703145\/zh802204003038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/10\/3038\/1703145\/zh802204003038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T03:38:29Z","timestamp":1581565109000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/104\/10\/3038\/18726\/FIP1L1PDGFRA-fusion-prevalence-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,15]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-03-0787","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,15]]}}}